RhumbLine Advisers’s Actinium Pharmaceuticals ATNM Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | – | Sell |
-42,284
| Closed | -$68.1K | – | 4148 |
|
|
2025
Q1 | $68.1K | Buy |
42,284
+1,564
| +4% | +$2.52K | ﹤0.01% | 3495 |
|
|
2024
Q4 | $51.3K | Buy |
40,720
+1,724
| +4% | +$2.17K | ﹤0.01% | 3647 |
|
|
2024
Q3 | $73.3K | Sell |
38,996
-660
| -2% | -$1.24K | ﹤0.01% | 3597 |
|
|
2024
Q2 | $293K | Buy |
39,656
+7,525
| +23% | +$55.7K | ﹤0.01% | 3015 |
|
|
2024
Q1 | $252K | Buy |
32,131
+483
| +2% | +$3.78K | ﹤0.01% | 3068 |
|
|
2023
Q4 | $161K | Buy |
31,648
+882
| +3% | +$4.48K | ﹤0.01% | 3285 |
|
|
2023
Q3 | $182K | Buy |
30,766
+1,116
| +4% | +$6.61K | ﹤0.01% | 3209 |
|
|
2023
Q2 | $220K | Buy |
+29,650
| New | +$220K | ﹤0.01% | 3192 |
|
|
2015
Q2 | – | Sell |
-469
| Closed | -$35K | – | 3035 |
|
|
2015
Q1 | $35K | Buy |
+469
| New | +$35K | ﹤0.01% | 3011 |
|